Telix Pharmaceuticals valuation

TLX · ASX · AUD

Compare Telix Pharmaceuticals
$13.25Change from previous close: −0.60%Absolute change: −$0.08

Close · November 18, 2026

Valuation

The P/E ratio is 88.9. The average price target of 11 analysts is $24.17.

Data as of November 17, 2026

Telix Pharmaceuticals compared with similar companies

Telix Pharmaceuticals's P/E (trailing 12 months): 88.9, +27% against the median of a group of 6 similar companies (69.8).

Telix Pharmaceuticals's metrics compared with similar companies
MetricTelix PharmaceuticalsMedian25th–75th percentileBand
P/E (trailing 12 months)88.969.844.5 – 95.0Middle
EV/EBITDA69.669.632.3 – 140.7Middle
Price/book6.535.103.40 – 7.63Middle
Price/sales5.0720.47.55 – 50.0Low
Gross margin47.6%77.3%49.8% – 84.4%Low
Operating margin6.2%14.9%-12.3% – 23.8%Middle
Net margin3.8%3.8%-61.6% – 25.3%Middle
ROE7.4%10.4%-1.8% – 35.7%Middle
Debt/equity1.190.160.05 – 0.41High

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$4.52B
Enterprise value
$4.86B
Forward P/E
-771.4
EV/revenue
5.45

Profitability and growth

ROA
2.7%
ROIC
3.6%
Revenue growth (year over year)
22.3%
Earnings growth (year over year)
-1,652.5%

Financial health

Total cash
$251.91M
Total debt
$579.86M
Current ratio
2.01
Quick ratio
1.74
Altman Z-Score
3.19
Piotroski F-Score
3.00

Dividends

Dividend yield
0.0%
Payout ratio
0.0%

Analysts and estimates

Average price target
$24.17
Median price target
$21.50
High price target
$31.50
Low price target
$18.80
Analysts with a price target
11
Consensus
Buy
Forward EPS
-$0.02
EPS estimate, current year
$0.07

Shares and trading

Beta
0.63
Average volume
2.17M
Shares outstanding
338.78M
Float
297.96M
Institutional ownership
34.3%
Insider ownership
15.8%